InspireMD (NYSE:NSPR) Insider Shane Thomas Gleason Sells 5,132 Shares

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 5,132 shares of InspireMD stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $2.46, for a total value of $12,624.72. Following the completion of the transaction, the insider owned 1,104,601 shares in the company, valued at approximately $2,717,318.46. This represents a 0.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shane Thomas Gleason also recently made the following trade(s):

• On Tuesday, May 19th, Shane Thomas Gleason sold 22,778 shares of InspireMD stock. The stock was sold at an average price of $1.01, for a total transaction of $23,005.78.

InspireMD Stock Performance

Shares of NSPR traded up $0.03 during mid-day trading on Thursday, reaching $1.03. The company had a trading volume of 160,140 shares, compared to its average volume of 182,457. The company has a market capitalization of $48.24 million, a price-to-earnings ratio of -1.37 and a beta of 0.82. The company’s 50 day simple moving average is $1.40 and its 200 day simple moving average is $1.68. InspireMD, Inc. has a 1-year low of $0.97 and a 1-year high of $2.93.

Institutional Investors Weigh In On InspireMD

A number of institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC bought a new stake in InspireMD during the 1st quarter worth approximately $29,000. Virtu Financial LLC bought a new stake in InspireMD during the 4th quarter worth approximately $31,000. XTX Topco Ltd bought a new stake in InspireMD during the 4th quarter worth approximately $30,000. Orbimed Advisors LLC grew its holdings in InspireMD by 46.9% during the 4th quarter. Orbimed Advisors LLC now owns 3,133,405 shares of the company’s stock worth $5,577,000 after acquiring an additional 1,000,000 shares during the last quarter. Finally, Essex Investment Management Co. LLC bought a new stake in InspireMD during the 4th quarter worth approximately $203,000. 44.78% of the stock is owned by institutional investors.

InspireMD News Summary

Here are the key news stories impacting InspireMD this week:

• Neutral Sentiment: Shane Thomas Gleason disclosed multiple recent sales of InspireMD shares, including transactions on May 19, May 23, May 27, May 29, May 30, and earlier January/February dates. Each filing says the sales were made to cover tax withholding obligations related to the vesting of equity awards, which makes the activity look more routine than a strategic exit. Article Title
• Neutral Sentiment: A new “Stock Forecast & Price Target” page for InspireMD may be contributing to increased trading interest, but the item itself does not include a specific rating change, earnings update, or business development that would clearly drive the shares. Article Title

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on NSPR shares. Lake Street Capital set a $4.00 price target on shares of InspireMD in a report on Monday, May 4th. Piper Sandler reiterated an “overweight” rating and issued a $3.00 price target (down from $4.00) on shares of InspireMD in a research note on Tuesday, May 5th. Maxim Group assumed coverage on InspireMD in a research note on Monday, February 2nd. They issued a “buy” rating and a $6.00 price target for the company. Finally, Loop Capital set a $5.00 price target on InspireMD in a research note on Tuesday, February 24th. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $4.50.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.